Thought Leadership Engager in Partnership with Natera

Go Faster. Move Earlier. Accelerating Development & Unlocking New Opportunities with ctDNA

• ctDNA continues to be explored as a tool to support treatment decision-making across multiple stages of cancer care
• This session will explore clinical and industry leaders perspectives on how ctDNA may inform decisions from neoadjuvant and adjuvant settings through treatment escalation, de-escalation, organ preservation and metastatic disease
• Attendees will break into three focused groups based on their role and interests